Literature DB >> 33781516

American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients.

Sanjeet S Dadwal1, Tobias M Hohl2, Cynthia E Fisher3, Michael Boeckh4, Genofeva Papanicolaou2, Paul A Carpenter5, Brian T Fisher6, Monica A Slavin7, D P Kontoyiannis8.   

Abstract

The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A completely fresh approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQs), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed, then answered FAQs, and finalized topics with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. This second guideline in the series focuses on invasive aspergillosis, a potentially life-threatening infection in the peri-HCT period. The relevant risk factors, diagnostic considerations, and prophylaxis and treatment approaches are reviewed.
Copyright © 2020 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antifungal prophylaxis; Antifungal therapy; Diagnosis; Invasive aspergillosis; Transplantation

Mesh:

Year:  2021        PMID: 33781516      PMCID: PMC9088165          DOI: 10.1016/j.jtct.2020.10.003

Source DB:  PubMed          Journal:  Transplant Cell Ther        ISSN: 2666-6367


  88 in total

1.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

2.  Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity.

Authors:  Jorien D'Haese; Koen Theunissen; Edith Vermeulen; Hélène Schoemans; Greet De Vlieger; Liesbet Lammertijn; Philippe Meersseman; Wouter Meersseman; Katrien Lagrou; Johan Maertens
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

3.  A Case Series and Literature Review of Isavuconazole Use in Pediatric Patients with Hemato-oncologic Diseases and Hematopoietic Stem Cell Transplantation.

Authors:  N Decembrino; K Perruccio; M Zecca; A Colombini; E Calore; P Muggeo; E Soncini; A Comelli; M Molinaro; B M Goffredo; S De Gregori; I Giardini; L Scudeller; S Cesaro
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation.

Authors:  Sanjeet S Dadwal; Bernard Tegtmeier; Xueli Liu; Paul Frankel; James Ito; Stephen J Forman; Vinod Pullarkat
Journal:  Eur J Haematol       Date:  2014-09-13       Impact factor: 2.997

Review 5.  Diagnostic Imaging and Invasive Fungal Diseases in Children.

Authors:  Aspasia Katragkou; Brian T Fisher; Andreas H Groll; Emmanuel Roilides; Thomas J Walsh
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

6.  The utility of bronchoalveolar lavage beta-D-glucan testing for the diagnosis of invasive fungal infections.

Authors:  Stacey R Rose; Saraschandra Vallabhajosyula; Miguel G Velez; Daniel P Fedorko; Mark J VanRaden; Juan C Gea-Banacloche; Michail S Lionakis
Journal:  J Infect       Date:  2014-05-04       Impact factor: 6.072

7.  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial.

Authors:  K A Marr; K Seidel; M A Slavin; R A Bowden; H G Schoch; M E Flowers; L Corey; M Boeckh
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

8.  Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.

Authors:  Catherine Cordonnier; Montserrat Rovira; Johan Maertens; Eduardo Olavarria; Catherine Faucher; Karin Bilger; Arnaud Pigneux; Oliver A Cornely; Andrew J Ullmann; Rodrigo Martino Bofarull; Rafael de la Cámara; Maja Weisser; Effie Liakopoulou; Manuel Abecasis; Claus Peter Heussel; Marc Pineau; Per Ljungman; Hermann Einsele
Journal:  Haematologica       Date:  2010-07-15       Impact factor: 9.941

9.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

Authors:  J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

Review 10.  Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children.

Authors:  Jill King; Zoi-Dorothea Pana; Thomas Lehrnbecher; William J Steinbach; Adilia Warris
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

View more
  2 in total

Review 1.  New Perspectives on Antimicrobial Agents: Isavuconazole.

Authors:  James S Lewis; Nathan P Wiederhold; Morgan Hakki; George R Thompson
Journal:  Antimicrob Agents Chemother       Date:  2022-08-15       Impact factor: 5.938

Review 2.  Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.

Authors:  Richard H Drew; John R Perfect
Journal:  J Fungi (Basel)       Date:  2022-02-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.